Please login to the form below

Not currently logged in
Email:
Password:

Watson chewable contraceptive approved

The US Food and Drug Administration has approved a new chewable, low-dose oral contraceptive from Watson Pharmaceuticals

The US Food and Drug Administration (FDA) has granted marketing clearance to a new chewable, low-dose oral contraceptive from Watson Pharmaceuticals. The product is the first and only low dose oral contraceptive to combine 0.8mg norethindrone and 0.025mg ethinyl estradiol in chewable form, according to the company.

The pill's dosing regimen, which includes 24 days of active hormones and four ferrous fumarate (iron) placebo tablets, is intended to give women a low level of breakthrough bleeding and short, light, predictable periods.

Watson, which has largely focused on generic drugs, licensed the product from a subsidiary of Warner Chilcott as part of its move to expand its branded offerings by forging partnerships with other companies. Under the licensing and supply agreement deal, which the companies signed in January 2009, Watson obtained an exclusive licence to market and sell the product, with Warner Chilcott agreeing to exclusively supply Watson with the drug on a cost-plus-margin basis in return for royalties based on net sales.

Watson plans to begin marketing the product to physicians through its Global Brands division beginning in the second quarter of 2011. 

The new drug application for the product included data from a 12-month, open-label phase III study that enrolled 1,251 women between the ages of 18 and 35. The data showed the drug prevented pregnancy and that the women had short, predictable periods, with a mean duration of 3.7 days, according to Watson.  

The product is not the first chewable birth control pill to hit the US market: Bristol Myers Squibb's Ovcon 35, a spearmint-flavored chewable contraceptive marketed by Warner Chilcott was approved by the FDA in 2003, and Warner Chilcott launched a similar product called Femcon Fe in 2006.

23rd December 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics